Screener
Collegium Pharmaceutical, Inc. COLL Symproic — Finite-Lived Intangible Assets, Accumulated Amortization
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.
The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:34 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053851
| Line item | June 30, 2026 / Cost | June 30, 2026 / Accumulated Amortization | June 30, 2026 / Carrying Amount | December 31, 2025 / Cost | December 31, 2025 / Accumulated Amortization | December 31, 2025 / Carrying Amount |
|---|---|---|---|---|---|---|
| Jornay PM | $635,000 | $(152,986) | $482,014 | $635,000 | $(111,072) | $523,928 |
| Azstarys | 635,000 | (7,480) | 627,520 | — | — | — |
| Belbuca | 360,000 | (322,305) | 37,695 | 360,000 | (284,607) | 75,393 |
| Nucynta Products | 521,170 | (521,170) | — | 521,170 | (493,478) | 27,692 |
| Symproic | 70,000 | (31,145) | 38,855 | 70,000 | (27,503) | 42,497 |
| Total intangible assets | $2,221,170 | $(1,035,086) | $1,186,084 | $1,586,170 | $(916,660) | $669,510 |
Item 1. Condensed Consolidated Financial Statements (Unaudited).
FAQ
- What is Collegium Pharmaceutical, Inc.'s symproic — finite-lived intangible assets, accumulated amortization?
- Collegium Pharmaceutical, Inc. (COLL) reported symproic — finite-lived intangible assets, accumulated amortization of $31.15M in Q2 2026.
- How has Collegium Pharmaceutical, Inc.'s symproic — finite-lived intangible assets, accumulated amortization changed year-over-year?
- Collegium Pharmaceutical, Inc.'s symproic — finite-lived intangible assets, accumulated amortization increased by 30.5% year-over-year, from $23.86M to $31.15M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s symproic — finite-lived intangible assets, accumulated amortization?
- Over 3 years (2022 to 2025), Collegium Pharmaceutical, Inc.'s symproic — finite-lived intangible assets, accumulated amortization has grown at a 104.1% compound annual growth rate (CAGR), from $11.66M to $99.08M.
- What does symproic — finite-lived intangible assets, accumulated amortization mean?
- The cumulative amount of amortization expense recognized for finite-lived intangible assets related to the Symproic product line. This figure tracks the historical consumption of the asset's economic value over its useful life.
Ask your AI about Collegium Pharmaceutical, Inc.'s symproic — finite-lived intangible assets, accumulated amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude